1. INTRODUCTION {#acm212216-sec-0001}
===============

Hippocampal injuries play a fundamental role both in short and long‐term memory loss and cognitive impairment.[1](#acm212216-bib-0001){ref-type="ref"}, [2](#acm212216-bib-0002){ref-type="ref"} Cranial irradiation can induce hippocampus damage, as suggested by some studies.[3](#acm212216-bib-0003){ref-type="ref"}, [4](#acm212216-bib-0004){ref-type="ref"}, [5](#acm212216-bib-0005){ref-type="ref"}, [6](#acm212216-bib-0006){ref-type="ref"}, [7](#acm212216-bib-0007){ref-type="ref"}, [8](#acm212216-bib-0008){ref-type="ref"}, [9](#acm212216-bib-0009){ref-type="ref"} In particular, cognitive impairment caused by whole brain irradiation (WBRT) has been investigated.[10](#acm212216-bib-0010){ref-type="ref"} These studies suggest that radiation‐induced neurocognitive toxicity occurs after irradiating neural stem cells of the hippocampus, potentially compromising patients quality of life (QoL).

WBRT has long been considered the mainstay treatment for patients with multiple brain metastases; nowadays, due to innovative technologies, fractioned stereotactic brain radiotherapy (FSBRT) and radiosurgery (SRS) can represent valid alternative therapeutic options to WBRT[11](#acm212216-bib-0011){ref-type="ref"}, [12](#acm212216-bib-0012){ref-type="ref"} allowing a better sparing of organs at risk, an improved outcome, and an increase in life expectancy; as a consequence, late onset radiation induced neurological sequels on hippocampi could be revealed in the course of life. Moreover, being the hippocampus very often close to the target, it could receive very high doses in extreme hypofractionated FSBRT treatments. Despite the large number of patients treated with these techniques, hippocampus is not routinely considered among organs at risk and the few clinical data available are not able to establish the correlation between dose on the hippocampus and cognitive effects. Results of the phase II RTOG 0933 study,[13](#acm212216-bib-0013){ref-type="ref"} show that some benefit in neuro‐cognitive functioning is achieved by hippocampal‐sparing in brain radiotherapy; however, phase III trial studies are necessary to validate the approach and confirm these findings. In spite of the paucity of clinical data, many authors focus on the feasibility of hippocampal‐sparing (HS) treatment plans. They applied the HS approach to WBRT followed by a radio‐surgical boost or WBRT and simultaneous integrated boost treatments using highly conformal techniques such as IMRT, helical tomotherapy or VMAT[14](#acm212216-bib-0014){ref-type="ref"}, [15](#acm212216-bib-0015){ref-type="ref"}, [16](#acm212216-bib-0016){ref-type="ref"}, [17](#acm212216-bib-0017){ref-type="ref"}, [18](#acm212216-bib-0018){ref-type="ref"}, [19](#acm212216-bib-0019){ref-type="ref"} demonstrating that HS plans were effectively able to spare the commonly delineated OARs including the hippocampus, while maintaining the same dose coverage and homogeneity of target volumes as the original ones. In these studies, the reduction in mean hippocampus dose was used as parameter to evaluate the appropriateness of the HS plans.

With regard to issues mentioned above, we conducted a retrospective feasibility study which consisted in elaborating HS plans for 22 FSBRT patients treated with VMAT technique maintaining the same coverage and homogeneity on the targets as the original plans. The hippocampus was firstly retrospectively delineated on the 22 plans and the corresponding dose--volume histograms (DVHs) were evaluated. Plans exceeding dose constraints for the hippocampus, were replanned introducing in the inverse planning module the dose volume constraints reported in literature.[7](#acm212216-bib-0007){ref-type="ref"}, [13](#acm212216-bib-0013){ref-type="ref"} The reduction in mean hippocampal dose in the new plans compared to the original plans, was evaluated.

2. MATERIALS AND METHODS {#acm212216-sec-0002}
========================

2.A. Study design {#acm212216-sec-0003}
-----------------

The present study was a theoretical planning exercise aimed to test HS hippocampal sparing planning technique in FSBRT. We selected cases planned and treated using a VMAT technique without considering hippocampus as OAR; hippocampus was retrospectively delineated and hippocampus dose constraints were evaluated. To test HS VMAT feasibility, cases with hippocampus exceeding dose limits were re‐planned respecting original conformity and homogeneity indices.

2.B. Patients and methods {#acm212216-sec-0004}
-------------------------

A total of 22 cancer patients with 38 brain metastases were treated in FSBRT at the Radiotherapy Department, SS. Annunziata Hospital, University of Chieti. Sample and disease characteristics are reported in Table [1](#acm212216-tbl-0001){ref-type="table-wrap"}.

###### 

Patients and tumor characteristics

  Patients and disease characteristics   
  -------------------------------------- --------
  Age (yr)                               
  Median                                 65
  Range                                  48--84
  Gender (n)                             
  Female                                 15
  Male                                   7
  Karnofsky performance status (n)       
  70%                                    3
  80%                                    5
  90%                                    6
  100%                                   8
  Primary tumor (n)                      
  Lung                                   13
  Breast                                 5
  Colon‐rectum                           4
  Number of metastases (n)               
  1                                      15
  2                                      2
  3                                      1
  4                                      4
  Metastatic site (n)                    
  Cerebellum                             13
  Parietal lobe                          6
  Frontal lobe                           8
  Other                                  11
  Systemic disease control (n)           
  Yes                                    16
  No                                     6

John Wiley & Sons, Ltd

All patients underwent a 2 mm thick non‐contrast computed tomography (CT) slice simulation and the images were acquired from the vertex to the lower border of C2. A thermoplastic mask with 3 fixation points was used as immobilization system. A 2 mm thick Magnetic Resonance Imaging (MRI) slice using a 3 Tesla MR scanner and gadolinium contrast‐enhanced T1 weighting was acquired for all patients. CT simulation and MRI images were co‐registered on Oncentra External Beam version 4.5.2 (Elekta Ltd., Crawley, UK) using a rigid registration algorithm. This coregistration was used to contour the targets (a single structure called CTV has been used as the composite of all the lesions), and organs at risk (OARs) such as optic chiasm and brainstem. The other OARs (lens, eyes, optic nerves, spinal cord, cochleae) were contoured using only CT data. Based on retrospective analysis of our clinical records, to account for setup and other treatment uncertainties, the planning target volume (PTV) was generated by adding a geometrical isotropic expansion of 3--5 mm to the CTV; a smaller isotropic expansion margin (3 mm) was applied in cases of optimal MRI‐simulation CT co‐registration. 11 patients received a total dose of 20 Gy (5 Gy/4 fractions) and 11 received 24 Gy (8 Gy/3 fractions). All VMAT plans were generated using the Collapse Cone Convolution algorithm in Plan Optimization Module (Oncentra Optimizer VMAT version 4.5.2) and delivered using Elekta Synergy Agility and 6 MV or 10 MV energies. The Agility multileaf collimator (Elekta AB, Stockholm, Sweden) had 160 leaves of projected width 0.5 cm at the isocenter. Maximum leaf speed was 3.5 cm/s.

To improve dose calculation accuracy for smaller lesions, the planning system was accurately extrapolated down to a 1 × 1 cm^2^ field size. The plans consisted in two full coplanar arcs and additional non‐coplanar partial arches were added to the two coplanar arcs with a couch angle chosen to avoid organs at risk. The dose normalization was chosen to ensure 95% of PTV volume coverage by 98% of prescribed dose (PD) for all of VMAT plans. In order to achieve better PTV coverage and lower OARs dose values, all VMAT plans were inversely planned optimizing leaf and gantry rotation speed and dose rate as free parameters. In case of irradiation of multiple lesions, the isocenter was automatically located at the center of mass of the lesions.

CBCT was performed daily before each treatment session to evaluate set‐up errors. CBCT acquisition volume (clip‐box) was determined to include whole PTV and OARs. The 3D‐3DCBCT‐ CT planning scan co‐registration was performed using the Gray level algorithm.

2.C. Retrospective hippocampus study {#acm212216-sec-0005}
------------------------------------

The Hippocampus (H) was retrospectively delineated on the original plans by a radiation oncologist on gadolinium contrast‐enhanced T1‐weighted MRI. Delineation was performed on axial images using the RTOG 0933 atlas[20](#acm212216-bib-0020){ref-type="ref"} as reference. Afterwards, the contours in sagittal, coronal, and axial projections were revised by a neuroradiologist. A hippocampal avoidance zone (HAZ) was generated adding an isotropic 5 mm margin. The maximum dose (D~max~) and dose to 100% of hippocampus volume (D~100%~) were documented for all VMAT plans, according to the RTOG 0933 dosimetric compliance criteria.[13](#acm212216-bib-0013){ref-type="ref"} Moreover, the dose to 40% of hippocampus volume (D~40%~) was considered.[7](#acm212216-bib-0007){ref-type="ref"} Since RTOG hippocampal constraints were defined for a prescribed dose of 30 Gy in ten fractions, they were converted to biologically equivalent doses in 2 Gy fractions (EQD2). As the D~40%~constraint was more restrictive than D~100%~, the latter was no longer considered in this study.

Due to the alternative fractionation FSBRT schema, the analysis of DVHs was performed, for all the OARs, reconverting all dose values to equivalent doses in 2‐Gy fractions assuming an *α*/*β* ratio of 2 Gy.

In case original VMAT plans exceeded hippocampal constraints (non‐hippocampal‐sparing, NHS), HS plans were generated. The HS plans were elaborated following the same arc optimization systematic strategy as NHS regarding objectives, weights, and MU limit. Hippocampal constraints have been applied on HAZ. In addition, the distance between HAZ and the adjacent lesion was measured. The plan analysis included the evaluation of all the other OARs doses.

Dose delivery accuracy of all plans was assessed by measuring the 3D dose distributions with OCTAVIUS detector 729 device (PTW, Freiburg, Germany) and the agreement between measured and calculated dose profiles was checked using the gamma passing rate of 3% local dose (LD) and 3 mm distance to agreement (DTA) with a 10% threshold.

2.D. Dosimetric evaluation of VMAT plans {#acm212216-sec-0006}
----------------------------------------

Dosimetric evaluation of both NHS and HS plans was carried out by calculating conformity and homogeneity indexes. Healthy brain mean dose as a surrogate of the integral dose for said tissue[21](#acm212216-bib-0021){ref-type="ref"} was also evaluated.

The conformity index CI[22](#acm212216-bib-0022){ref-type="ref"} was defined as:$${CI} = \frac{V_{T,pi}^{2}}{V_{T} \times V_{pi}}$$where *V* ~*T,pi*~ was the volume of the target covered by the prescription isodose, *V* ~*T*~ was the target volume, and *V* ~*pi*~ was the volume of the prescription isodose. The homogeneity index (HI),[23](#acm212216-bib-0023){ref-type="ref"} was computed as the ratio of the Maximum Dose (MD) to the PD. $$\text{HI} = \frac{MD}{PD}$$

In presence of multiple PTVs, their cumulative volume was considered.

CI and HI values near to 1 correspond to more homogenous and conformal irradiation of the target volume. In the text, we refer to these indexes as CI~NHS~ and HI~NHS~ or CI~HS~ and HI~HS~ for NHS and HS plans respectively.

The plans were considered acceptable if the CI~HS~ and HI~HS~ values were found within ± 5% of CI~NHS~ and HI~NHS~ respectively. Maximum dose and doses to 40% of hippocampal volume (D~max~ and D~40%~, respectively) values were registered and compared to those of the corresponding NHS plans.

To evaluate healthy brain mean dose (NTMD), an additional structure \[called non‐tumor (NT)\] consisting of brain minus PTV was created. From DVHs, the mean doses were then extracted both for NHS (NTMD~NHS~) and HS (NTMD~HS~) plans.

3. RESULTS {#acm212216-sec-0007}
==========

Twenty‐two patients with 38 brain metastases were evaluated. Mean volumes for PTV and H were 5.7 cm^3^ (range 1--23.6) and 4.5 cm^3^ (range 2--6) respectively. The closest distance between the lesion and the hippocampal surface was found to be 2 mm (mean distance = 11.7 ± 6 mm). In NHS, the mean values of CI and HI were 0.79 ± 0.11 (range 0.54--0.93) and 1.05 ± 0.02 (range 1.02--1.08) respectively.

In 9/22 and 6/22 cases, D~max~ and D~40%~ constraints for HZA exceeded respectively. Constraints were not respected in patients with more than one metastatic lesion (six patients) and in three patients with only one lesion. For the nine plans exceeding D~max~ for HZA, hippocampal‐sparing plans were retrospectively elaborated.

For the new plans (HS plans), mean values of CI~HS~ and HI~HS~ were 0.81 ± 0.10 (range 0.59--0.92) and 1.04 ± 0.01 (range 1.03--1.07) respectively. These values were similar to CI~NHS~ and HI~NHS~ reported above although no statistical significance was found applying the *Pearson* chi‐square *test*, (*P* = 0.75).The lowest CI values, were observed for patients with more than one brain metastases.

HS plans maintained comparable MU values to NHS plans (mean MU values: 1033 ± 275 and 1022 ± 234 for NHS and HS respectively).

Table [2](#acm212216-tbl-0002){ref-type="table-wrap"} reports CI and HI values for both NHS and HS plans (CI~NHS~ and HI~NHS~, CI~HS~ and HI~HS~), and all the distances from H to the closest lesion of nine patients with VMAT replanning. Table [3](#acm212216-tbl-0003){ref-type="table-wrap"} reports NTMD values, both for NHS and HS plans (NTMD~NHS~ and NTMD~HS~) respectively. Mean NTMD~NHS~ value was found comparable with mean NTMD~HS~ (3.8 ± 1.2 Gy for NHS and 3.7 ± 0.9 Gy for HS plans, *P* = 0.73).

###### 

CI and HI values for both NHS and HS plans of 9 patients with VMAT re‐planning. The last column reports the distance from H to closet target

  \# Patient   \# Target   CI~NHS~   CI~HS~   HI~NHS~   HI~HP~   Distance from H to target (mm)
  ------------ ----------- --------- -------- --------- -------- --------------------------------
  1            4           0.76      0.78     1.08      1.05     22
  2            2           0.70      0.76     1.02      1.07     7
  3            1           0.91      0.90     1.06      1.05     15
  4            4           0.54      0.59     1.06      1.05     12
  5            4           0.80      0.84     1.05      1.03     15
  6            2           0.83      0.83     1.04      1.04     15
  7            3           0.74      0.79     1.04      1.04     6
  8            1           0.84      0.88     1.02      1.04     2
  9            1           0.93      0.92     1.04      1.04     11
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###### 

NT mean doses (NTMD) for NHS and HS plans

  \# Patient   \# Fractions   \# Target   NTMD~NHS~ (Gy)   NTMD~HS~ (Gy)
  ------------ -------------- ----------- ---------------- ---------------
  1            5              4           4.3              4.4
  2            5              2           4.2              3.9
  3            5              1           1.8              1.8
  4            5              4           4.0              3.8
  5            5              4           4.7              4.5
  6            8              2           3.5              3.6
  7            8              3           5.3              4.9
  8            8              1           3.0              2.9
  9            8              1           3.4              3.6
  Mean ± SD                               3.8 ± 1.2        3.7 ± 0.9

John Wiley & Sons, Ltd

Regarding constraints, passing from NHS to HS plans both for H and HZA, D~max~ decreased of 16% for H and 7% for HZA; a more pronounced variation was found for D~40%~ in HS plans with a decrease in about 40% both for H and HZA.

All D~max~ and D~40%~ values with dose values exceeding the constraints highlighted in gray, are recorded in Tables [4](#acm212216-tbl-0004){ref-type="table-wrap"} and [5](#acm212216-tbl-0005){ref-type="table-wrap"}. As shown in Table [4](#acm212216-tbl-0004){ref-type="table-wrap"}, only 45% (4/9) of NSH plans with HAZ dose values exceeding D~max~ (max dose limit = 21.3 Gy) met the constraint after replanning. The number of HS plans respecting H constraints, increased slightly passing from 6/9 to 7/9 (about 78%). From the comparison of values reported in Tables [4](#acm212216-tbl-0004){ref-type="table-wrap"} and [5](#acm212216-tbl-0005){ref-type="table-wrap"} and those reported in Table [2](#acm212216-tbl-0002){ref-type="table-wrap"}, it can be deduced that the constraints were not respected in the case of the minimum hippocampus‐targets distance less than 12 mm. The closer hippocampus is to the target, the harder is to reduce the maximum dose without compromising target coverage.

###### 

D~max~ values of 9 re‐planned cases. Dose values exceeding the constraints are highlighted in gray

  \# Patient   \# Fractions   H             HAZ                         
  ------------ -------------- ------------- ------------- ------------- -------------
  1            5              12.9          10.5          21.8          15.2
  2            5              29.9          15.7          34.1          33.9
  3            5              10.5          7.9           24.5          17.0
  4            5              20.9          21.0          28.7          28.2
  5            5              20.4          15.3          24.0          21.0
  6            8              15.5          12.8          23.8          20.0
  7            8              39.8          36.7          54.6          55.6
  8            8              58.9          59.0          60.5          61.1
  9            8              17.0          11.7          27.1          26.4
  Mean ± SD                   25.1 ± 15.6   21.2 ± 16.5   33.2 ± 14.3   30.9 ± 16.6

John Wiley & Sons, Ltd

###### 

D~40%~ values of 9 replanned cases. Values exceeding the constraints are highlighted in gray

  \# Patient   \# Fractions   H           HAZ                     
  ------------ -------------- ----------- ----------- ----------- -----------
  1            5              6.0         5.3         5.7         5.3
  2            5              10.7        5.5         9.7         5.4
  3            5              4.6         4.4         3.9         3.8
  4            5              8.9         7.0         7.7         6.4
  5            5              12.4        7.3         11.4        7.3
  6            8              10.3        5.4         9.9         6.4
  7            8              12.3        5.3         12.6        6.2
  8            8              13.7        4.8         13.7        6.1
  9            8              5.9         4.6         5.4         4.4
  Mean ± SD                   9.4 ± 3.3   5.5 ± 1.0   8.9 ± 3.4   5.7 ± 1.0

John Wiley & Sons, Ltd

A different result was obtained for D~40%.~ After re‐planning, D~40%~ constraint value (7.3 Gy) was met for all six NHS plans that originally did not comply for both H and HZA independent from the distance of the hippocampus from the target.

Three of the original plans had D~40%~ within the constraint for both H and HZA, but exceeded D~max~ constraint, so replanning was performed.

Finally, mean hippocampus doses decreased by an average of 35% in HS plans reaching values of 7.0 ± 3.4 Gy and 7.3 ± 3.2 Gy as compared to 9.9 ± 5.3 Gy and 9.8 ± 5.1 Gy in NHS plans for H and HAZ respectively.

Dose received by other evaluated OARs resulted below the constraints in both NHS and HS plans.

The DVH and 3D structure view of an HS plan for one representative patient (Patient \# 6) is shown in Figs. [1](#acm212216-fig-0001){ref-type="fig"}(a) and [1](#acm212216-fig-0001){ref-type="fig"}(b), respectively. For this plan, both NHS and HS plan had the same CI (0.83) and H values (1.04). D~max~ and D~40%~ changed from 15.5 Gy to 12.8 Gy and 10.3 Gy to 5.4 Gy, respectively, for H and from 23.8 Gy to 20.0 Gy and 9.9 Gy to 6.4 Gy, respectively, for HZA.

![A cumulative normalized dose--volume histogram for hippocampus, hippocampal avoidance zone, and planning target volumes (PTV1 and PTV2) both in NHS and HS plans (Patient \# 6 with two lesions) (a); the corresponding 3D structure view (b).](ACM2-19-86-g001){#acm212216-fig-0001}

Figures [2](#acm212216-fig-0002){ref-type="fig"} and [3](#acm212216-fig-0003){ref-type="fig"} show two different axial sections (z = 26 mm and z = 16 mm, respectively) of the corresponding dose distribution. Figure [2](#acm212216-fig-0002){ref-type="fig"} represents the axial view referred to (a) NHS; (b) HS plan. By comparing (a) and (b), no significant difference in dose distribution seems to exist. The situation changes if we consider the axial section corresponding to z = 16 mm, shown in Fig. [3](#acm212216-fig-0003){ref-type="fig"}. In (c) (NHS plan), the 6 Gy isodose is inside HZA structure and touches H; in (d) it slightly touches HAZ (HS plan) only, with a greater dose sparing for both HZA and H.

![Spatial dose distributions in axial view for a representative NHS (a) and HS (b) VMAT plans (Patient \# 6). In the box of Fig. [1](#acm212216-fig-0001){ref-type="fig"} the contoured regions are listed. Blue isodose represents 6 Gy (D25%);green, 12 Gy (D50%) and yellow 22.8 Gy (D95%). Total dose of 24 Gy, in three fractions.](ACM2-19-86-g002){#acm212216-fig-0002}

![Spatial dose distributions in axial view for the same representative patient but taken in a different slice. In the box of Fig. [1](#acm212216-fig-0001){ref-type="fig"} the contoured regions are listed. Blue isodose represents 6 Gy (D25%);green, 12 Gy (D50%), and yellow 22.8 Gy (D95%). Total dose of 24 Gy, in three fractions.](ACM2-19-86-g003){#acm212216-fig-0003}

All treatment plans presented gamma passing rate of at least 91% (LD = 3%, DTA = 3 mm).

4. DISCUSSION {#acm212216-sec-0008}
=============

The role of the hippocampus in memory function is well‐established in literature[1](#acm212216-bib-0001){ref-type="ref"}, [2](#acm212216-bib-0002){ref-type="ref"}; although some studies affirm that cranial irradiation may damage neurogenic stem cells located in the subgranular layer of the hippocampal dentate gyrus inducing neurocognitive toxicity,[3](#acm212216-bib-0003){ref-type="ref"}, [4](#acm212216-bib-0004){ref-type="ref"}, [5](#acm212216-bib-0005){ref-type="ref"}, [24](#acm212216-bib-0024){ref-type="ref"}, [25](#acm212216-bib-0025){ref-type="ref"} dose constraints for hippocampus have not yet been elucidated, making it difficult to establish the potential benefits of hippocampal‐sparing approach. Some constraints were derived from the initial results of an analysis of patients affected by brain metastasis undergoing WBRT (D~max~ \< 16 Gy and D~100%~ \< 9 Gy at 3 Gy per fraction for a total dose of 30 Gy) and low/high grade gliomas receiving fractionated stereotactic radiation therapy (D~40%~ \< 7.3 Gy on bilateral hippocampus at 2 Gy per fraction).[7](#acm212216-bib-0007){ref-type="ref"}, [10](#acm212216-bib-0010){ref-type="ref"}, [13](#acm212216-bib-0013){ref-type="ref"}

D~max~ and D~100%~ constraints were also adopted by Pokhrel et al.[26](#acm212216-bib-0026){ref-type="ref"} who retrospectively investigated the plan quality and accuracy of using hippocampal‐sparing intensity modulated arc therapy in WBRT treatments.

In another works, the mean dose was considered as dose reference to optimize plans in a hippocampal‐sparing approach when highly conformal techniques such as IMRT, helical tomotherapy or VMAT are used.[14](#acm212216-bib-0014){ref-type="ref"}, [15](#acm212216-bib-0015){ref-type="ref"}, [16](#acm212216-bib-0016){ref-type="ref"}, [17](#acm212216-bib-0017){ref-type="ref"} Gondi et al[14](#acm212216-bib-0014){ref-type="ref"} compared HS plans with standard WBRT ones where a homogenous dose 30 Gy was applied to the whole brain including hippocampus. HS plans aimed to decrease the mean hippocampal dose obtaining 5.5 Gy (D~max~ 12.8 Gy) and 7.8 Gy (D~max~ 15.3 Gy) values for helical tomotherapy and LINAC based RT respectively. Gutierrez et al[15](#acm212216-bib-0015){ref-type="ref"} and Hsu et al[16](#acm212216-bib-0016){ref-type="ref"} focused on elaborating plans with mean dose in WBRT simultaneous integrated boost treatments followed by radio‐surgical boost or WBRT using tomotherapy[15](#acm212216-bib-0015){ref-type="ref"} and VMAT[16](#acm212216-bib-0016){ref-type="ref"} techniques respectively. The mean dose was also considered as a parameter that should be considered for developing hippocampal‐sparing strategies in patients undergoing WBRT followed by radio‐surgical boost[18](#acm212216-bib-0018){ref-type="ref"} or WBRT and simultaneous integrated boost[19](#acm212216-bib-0019){ref-type="ref"} treated with VMAT. Hippocampal avoidance strategies have been also implemented for locally advanced nasopharyngeal carcinoma[9](#acm212216-bib-0009){ref-type="ref"} and in radiosurgery of multiple intracranial targets using Gamma Knife Perfection^®^ equipment.[27](#acm212216-bib-0027){ref-type="ref"} Both studies confirm the reduction in mean hippocampal dose up to 35% in hippocampal‐sparing replanned cases, maintaining the same conformity and target coverage. Furthermore, it should be clarified if hippocampus dose constraints should be applied only to hippocampus or else to hippocampal avoidance zone. However, some authors indirectly suggest the "non‐applicability" of constraints to HAZ observing that sparing HAZ (hippocampus + 5 mm margin) poses a theoretical risk of disease progression in the margin region.[6](#acm212216-bib-0006){ref-type="ref"}

Taking into account these issues, we evaluated the feasibility of using VMAT to deliver FSBRT with hippocampal avoidance. To our knowledge, similar data do not exist in literature, either considering H or HZA. In this study, we replanned 9 of 22 FSRT VMAT plans (HS plans) since they had both HA and HAZ exceeding the considered EQD2 limits which were: D~max~ \< 21.3 Gy and D~40%~ \< 7.3 Gy, respectively.[7](#acm212216-bib-0007){ref-type="ref"}, [10](#acm212216-bib-0010){ref-type="ref"}, [13](#acm212216-bib-0013){ref-type="ref"} HS VMAT plans, maintained the same conformity (*P* = 0.75) and homogeneity (*P* = 0.72) of the original plans (NHS). The mean CI~NHS~ and CI~HS~ values were: 0.79 ± 0.11 and 0.81 ± 0.10 respectively. These were in good agreement with data reported in literature, for multiple no coplanar arcs in VMAT techniques in presence of single or multiple cranial lesions and single isocenter[28](#acm212216-bib-0028){ref-type="ref"}, [29](#acm212216-bib-0029){ref-type="ref"}, [30](#acm212216-bib-0030){ref-type="ref"}. In particular, we found the same dependence of the average CI values on the number of lesions. Infact, our values spread from 0.59 in case of 4 lesions to 0.92 in case of 1 lesion and HS. In literature, an average value of 0.86 is reported in the case of two lesions[29](#acm212216-bib-0029){ref-type="ref"} and an lower average value of 0.63[30](#acm212216-bib-0030){ref-type="ref"} in case of multiple lesions. Regarding HI, Wang et al.[30](#acm212216-bib-0030){ref-type="ref"} reported a mean value of 1.15 ± 0.03 higher than our (1.05 ± 0.02 in the NHS plans and 1.04 ± 0.01 in the HS plans); the higher number of lesions treated by Wang, however, could have limited the homogeneity of the plans. Our results show that plan quality after hippocampal sparing is still well within the published standards of conformity and homogeneity. Mean NTMD~NHS~ value was found comparable with mean NTMD~HS~ (*P* = 0.73). This means that changing treatment parameters passing from NHS to HS plans maintaining the same target coverage does not increase the total energy deposited to the healthy brain.

In our retrospective analysis, we found that 9 of 22 cases had D~max~ above the limits; 45% of them were recovered for HAZ (4/9 plans); one more plan was recovered for H (they passed from 6/9 to 7/9 plans!); dose values at 40% of volume (D~40%~) in HS plans were all recovered, both for H and HAZ. For HS plans presenting target adjacent to H (less than 12 mm) D~max~ was not recovered, regardless the number of the lesions and dose prescription.

Even though mean doses in HS plans were not considered as constraints in the optimization strategy, the obtained values were in good agreement with the values reported in literature and close to the constraint proposed by several authors (6 Gy).[14](#acm212216-bib-0014){ref-type="ref"}, [15](#acm212216-bib-0015){ref-type="ref"}, [16](#acm212216-bib-0016){ref-type="ref"}, [18](#acm212216-bib-0018){ref-type="ref"} However, it is difficult to compare our data with literature evidence, because dose prescription and fraction number are different, compared to similar studies regarding RT treatments for patients affected by metastatic brains but treated with different techniques, prescription doses and volumes (mainly WBRT followed by a sequential boost, or WBRT with concomitant boost). In any case, we noticed a reduction in about 35% in the mean dose and D~40%~ of hippocampal volume in HS plan in comparison to NHS plans suggesting that these two parameters are more sensible than D~max~ to optimization procedures.

In summary, our data suggest that for FSBRT performed with VMAT technique (a) targets adjacent to hippocampus could only partially benefit from an hippocampal‐sparing approach, in case good conformity and target coverage is needed considering D~max~ as a rigid constraint in the optimization tool; and (b) the doses undergoing a more important decrease (mean dose and D~40%~), may benefit much more from HS approach. On the other hand, our HS plans were optimized with respect to D~max~ and D~40%~. In a future work, we intend to investigate the impact of D~40%~ and the mean dose as constraints in the optimization tool in HS approach and use the constraint on D~max~ only in selected cases. In any case, the total number of MU did not change significantly among NHS and HS plans, so we think that an hippocampal‐sparing approach should always be attempted.

5. CONCLUSION {#acm212216-sec-0009}
=============

This study suggests that hippocampal‐sparing approach in fractionated stereotactic brain radiotherapy VMAT treatments is feasible, resulting in an overall decreased dose to the hippocampus. HS plans maintain the same target conformity and homogeneity, the same mean dose to surrounding healthy tissues and the same treatment time of the original plans. In case of hippocampal distance from the target larger than 12 mm, all the considered dose constraints are respected. Anyhow, a reduction in 35% has been obtained for the mean dose and D~40%~. Although safe threshold doses for the hippocampus have not been defined yet, it is strongly advisable to delineate the hippocampus and put in practice all the necessary strategies to reduce doses especially in patients with a reasonable life expectancy.
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